TATAINVEST Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹40 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Tata Elxsi delivered Q4 FY26 revenue of INR 993.8 crore with 0.9% QoQ CC growth, a flattish quarter. Transportation remained stable (+0.2% QoQ CC) with strategic wins from new-age OEMs, now representing 77% of transportation revenue. Healthcare underperformed significantly, declining 13.1% QoQ CC due to delayed deal closures (pushed to Q1 FY27). Media & Communications rebounded with 5.6% QoQ CC growth driven by ramp-ups and a large device OEM win. EBITDA margin expanded 130bps sequentially to 24.6%, driven by 155bps currency tailwind, 65bps operating leverage, partially offset by 90bps salary impact. Management revised FY27 growth guidance downward from double-digit to high single-digit, acknowledging geopolitical uncertainty and delayed deal momentum. The company targets 27% PBT margin by Q4 FY27 exit, achievable through gradual improvement aligned with top-line recovery. Key risks include Healthcare deal execution uncertainty, competitive pricing aggression from AI-capable peers, and automotive sector volatility amid geopolitical headwinds.
Colored figures show movement against the previous available record.
Guidance to track
- Management revised FY27 growth outlook downward from double-digit to high single-digit, citing geopolitical uncertainty, delayed deal momentum, and mixed customer signals across verticals.
- CFO Gaurav Bajaj indicated target to exit FY27 at 27% PBT level (not EBITDA), up from current levels, with improvements gradual and aligned to top-line recovery rather than dramatic sequential jumps.
Risks flagged
- Two large deals that were expected to close in Q4 were delayed by over 6 months. While management expects closure in Q1 FY27, any further slippage could materially impact FY27 revenue trajectory.
- Management acknowledged seeing irrational pricing from competitors claiming GenAI-driven productivity gains, though questioned whether this is sustainable given regulatory constraints in automotive/healthcare verticals.
- Despite winning new OEM deals in Q4, management flagged ongoing geopolitical uncertainty affecting customer decision-making and deal timing in transportation vertical.
- Nitin Pai explicitly stated the segment is 'not out of the woods' given ongoing M&A consolidation, top-line pressure at telcos/streaming companies, and reliance on cost-takeout deals rather than innovation spending.
Key quotes
- We were hoping on a couple of deals because we were very close to signing those deals, and those were large deals that could have really helped us with improving the numbers. Unfortunately, both those deals did not come through in the quarter, and they have been pushed to Q1.
- ER&D is not very large deals locked in for five years and so on. It is a set of projects that continue to run off. Every quarter, you will lose 10%, 15% revenues. You have to make it up with new deals and new contracts. That is the challenge.
- I think we're not seeing irrationality that you indicated. There are a few cases here and there, but we're not sure whether it is GenAI or some other factor that's applying.
Research modules